ReviewCell biochemistry and biophysics2025
"Carnosine-Niosomal Delivery System for Targeted Cancer Therapy".
Review in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "L-Ornithine Liposomal Nanoparticles Targeting the Proline Cycle: A Mechanistic Perspective for Ammonia-Driven Hepatic Encephalopathy".Cell biochemistry and biophysics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is considered to be among the main causes of death worldwide. Treatment options for cancer are numerous. The type of cancer and its stage of progression determine which kind of treatment is needed. Nanomedicine is a new field for the treatment of various diseases. Pharmaceutical nanocarriers can be fabricated from various materials such as polymers, metals, or lipid-based surfactants. Carnosine-loaded niosomes have emerged as a promising approach in targeted cancer therapy, offering potential advantages over conventional treatments such as chemotherapy and radiation, by improving drug delivery specificity and reducing side effects. The study demonstrates that the encapsulation of carnosine in niosomes enhances its stability and bioavailability, leading to a significant increase in anticancer efficacy. These findings suggest that niosome technology can serve as an effective delivery system for carnosine, potentially transforming its use in cancer treatment and paving the way for future research in targeted therapies. Nanomaterials provide a good delivery system for this method of treatment. It's used in the treatment and diagnosis of diseases. Numerous investigations have been conducted on nanoscale vesicular systems, such as the most recent generations of vesicular nanocarriers, liposomes, and niosomes. Lipophilic and hydrophilic bioactive chemicals are transported via the niosomes in a vesicle. Since niosomes are composed of non-ionic surfactants mixed with cholesterol or other amphiphilic substances, they have a wide range of applications. The therapy of cancer with carnosine-loaded niosomes is one of these uses. The body synthesizes carnosine, a histidine-containing dipeptide, by enzymatically mixing L-histidine and β-alanine. With its antioxidant activities, Carnosine is considered a drug that can reduce and treat cancerous cells and many other therapeutic applications.
Indexed as
Identifiers
39656368What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.